119 related articles for article (PubMed ID: 22226738)
1. Regulation of monocyte chemoattractant protein-1 through angiotensin II type 1 receptor in prostate cancer.
Shirotake S; Miyajima A; Kosaka T; Tanaka N; Kikuchi E; Mikami S; Okada Y; Oya M
Am J Pathol; 2012 Mar; 180(3):1008-1016. PubMed ID: 22226738
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylated Akt up-regulates angiotensin II type-1 receptor expression in castration resistant prostate cancer.
Kosaka T; Miyajima A; Shirotake S; Kikuchi E; Oya M
Prostate; 2011 Oct; 71(14):1510-7. PubMed ID: 21321983
[TBL] [Abstract][Full Text] [Related]
3. Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer.
Kosaka T; Miyajima A; Shirotake S; Kikuchi E; Hasegawa M; Mikami S; Oya M
Prostate; 2010 Feb; 70(2):162-9. PubMed ID: 19760626
[TBL] [Abstract][Full Text] [Related]
4. Induction of monocyte chemoattractant protein-1 expression by angiotensin II in the pancreatic islets and beta-cells.
Chipitsyna G; Gong Q; Gray CF; Haroon Y; Kamer E; Arafat HA
Endocrinology; 2007 May; 148(5):2198-208. PubMed ID: 17303665
[TBL] [Abstract][Full Text] [Related]
5. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
Nagai N; Izumi-Nagai K; Oike Y; Koto T; Satofuka S; Ozawa Y; Yamashiro K; Inoue M; Tsubota K; Umezawa K; Ishida S
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4342-50. PubMed ID: 17724226
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer.
Kosaka T; Miyajima A; Takayama E; Kikuchi E; Nakashima J; Ohigashi T; Asano T; Sakamoto M; Okita H; Murai M; Hayakawa M
Prostate; 2007 Jan; 67(1):41-9. PubMed ID: 17044086
[TBL] [Abstract][Full Text] [Related]
7. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice.
Dol F; Martin G; Staels B; Mares AM; Cazaubon C; Nisato D; Bidouard JP; Janiak P; Schaeffer P; Herbert JM
J Cardiovasc Pharmacol; 2001 Sep; 38(3):395-405. PubMed ID: 11486244
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling.
Du N; Feng J; Hu LJ; Sun X; Sun HB; Zhao Y; Yang YP; Ren H
Oncol Rep; 2012 Jun; 27(6):1893-903. PubMed ID: 22426690
[TBL] [Abstract][Full Text] [Related]
10. Reactive oxygen species-mediated signaling pathways in angiotensin II-induced MCP-1 expression of proximal tubular cells.
Tanifuji C; Suzuki Y; Geot WM; Horikoshi S; Sugaya T; Ruiz-Ortega M; Egido J; Tomino Y
Antioxid Redox Signal; 2005; 7(9-10):1261-8. PubMed ID: 16115031
[TBL] [Abstract][Full Text] [Related]
11. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination.
Suganuma T; Ino K; Shibata K; Kajiyama H; Nagasaka T; Mizutani S; Kikkawa F
Clin Cancer Res; 2005 Apr; 11(7):2686-94. PubMed ID: 15814650
[TBL] [Abstract][Full Text] [Related]
12. Candesartan inhibits LPS-induced expression increase of toll-like receptor 4 and downstream inflammatory factors likely via angiotensin II type 1 receptor independent pathway in human renal tubular epithelial cells.
Zhao LQ; Huang JL; Yu Y; Lu Y; Fu LJ; Wang JL; Wang YD; Yu C
Sheng Li Xue Bao; 2013 Dec; 65(6):623-30. PubMed ID: 24343720
[TBL] [Abstract][Full Text] [Related]
13. N-cadherin mediates angiogenesis by regulating monocyte chemoattractant protein-1 expression via PI3K/Akt signaling in prostate cancer cells.
Nalla AK; Estes N; Patel J; Rao JS
Exp Cell Res; 2011 Oct; 317(17):2512-21. PubMed ID: 21855541
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer.
Takahashi S; Uemura H; Seeni A; Tang M; Komiya M; Long N; Ishiguro H; Kubota Y; Shirai T
Prostate; 2012 Oct; 72(14):1559-72. PubMed ID: 22430461
[TBL] [Abstract][Full Text] [Related]
15. Lesion progression in apoE-deficient mice: implication of chemokines and effect of the AT1 angiotensin II receptor antagonist irbesartan.
Martin G; Dol F; Marés AM; Berezowski V; Staels B; Hum DW; Schaeffer P; Herbert JM
J Cardiovasc Pharmacol; 2004 Feb; 43(2):191-9. PubMed ID: 14716205
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1.
Proudfoot JM; Croft KD; Puddey IB; Beilin LJ
J Pharmacol Exp Ther; 2003 Jun; 305(3):846-53. PubMed ID: 12626661
[TBL] [Abstract][Full Text] [Related]
17. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II type 1 receptor antagonist suppress angiogenesis and growth of gastric cancer xenografts.
Huang W; Wu YL; Zhong J; Jiang FX; Tian XL; Yu LF
Dig Dis Sci; 2008 May; 53(5):1206-10. PubMed ID: 17934850
[TBL] [Abstract][Full Text] [Related]
19. WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages.
Lee GT; Kwon SJ; Kim J; Kwon YS; Lee N; Hong JH; Jamieson C; Kim WJ; Kim IY
Br J Cancer; 2018 Mar; 118(5):670-678. PubMed ID: 29381686
[TBL] [Abstract][Full Text] [Related]
20. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis.
Candido R; Allen TJ; Lassila M; Cao Z; Thallas V; Cooper ME; Jandeleit-Dahm KA
Circulation; 2004 Mar; 109(12):1536-42. PubMed ID: 15023892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
